title: Efficacy and tolerability of multiple-dose SDZ IMM 125 in patients with severe psoriasis.
abstract: Although cyclosporin is effective in immunosuppression following organ transplantation and in the treatment of psoriasis, its use is limited by its side-effects, notably impaired renal function and hypertension. As SDZ IMM 125, a new derivative of the cyclosporin family, showed considerable immunosuppressive activity in experimental studies, with less effect on renal function, it was considered a potential successor to cyclosporin for both indications. In this multicentre, double-blind, placebo-controlled study, the efficacy and tolerability of 40, 100, 200 and 400 mg SDZ IMM 125 daily were studied in 59 patients with psoriasis. Patients were followed for a period of 5 weeks (4 weeks treatment, and 1 week post-treatment observation). A dose-dependent effect of SDZ IMM 125 was observed. A significant correlation was found between the dose of SDZ IMM 125 and changes in the sum of severity scores of three indicator plaques. There was a significant decrease in the body surface area affected by psoriasis in the 400-mg group (P < or = 0.01), whereas a decrease of the global psoriasis severity was observed in the 200-mg (P < or = 0.01) and the 400-mg groups (P < or = 0.001). No serious adverse events occurred during the 4 weeks of treatment. Three patients discontinued treatment because of adverse events (one sore throat, two influenza). Clinical adverse events were similar to those reported with cyclosporin, the most frequent being gastrointestinal disturbances. Estimation of renal function indices showed that increases from baseline values were dose-dependent, and appeared to be similar to those seen with cyclosporin.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Academisch Medisch Centrum, University of Amsterdam, The Netherlands.
authors.forename: L
authors.initials: L
authors.lastname: Witkamp
authors.forename: I M
authors.initials: IM
authors.lastname: Zonneveld
authors.forename: E G
authors.initials: EG
authors.lastname: Jung
authors.forename: R E
authors.initials: RE
authors.lastname: Schopf
authors.forename: E
authors.initials: E
authors.lastname: Christophers
authors.forename: R
authors.initials: R
authors.lastname: Grossman
authors.forename: H
authors.initials: H
authors.lastname: Meffert
authors.forename: S
authors.initials: S
authors.lastname: Belaich
authors.forename: G
authors.initials: G
authors.lastname: Mahrle
authors.forename: T
authors.initials: T
authors.lastname: Van Joost
mesh_terms: D000328:Adult; D003524:Cyclosporins / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology
chemical_list: D003524:Cyclosporins; D007166:Immunosuppressive Agents; C075935:SDZ IMM 125